We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer-Medivation Close to Signing $14B Acquisition Deal?
Read MoreHide Full Article
According to a Financial Times article, Pfizer Inc. (PFE - Free Report) and Medivation, Inc. are close to signing a deal under which Pfizer will acquire Medivation for more than $80 per share (approximately $14 billion).
Medivation has been a part of acquisition talks for quite a while with the company first receiving an offer from French drugmaker Sanofi (SNY - Free Report) . Sanofi had initially approached Medivation with an offer of $52.50 in cash which was rejected by the company.
Last month, Medivation announced that it is open to acquisition talks and entered into confidentiality agreements with several firms that had expressed an interest in exploring a potential transaction. The company also confirmed that it had rejected a sweetened bid from Sanofi under which Sanofi offered $58.00 per share in cash plus a Contingent Value Right (CVR) for talazoparib sales representing a potential payment in 2022 of up to $3.00 per share.
Pfizer’s rumored offer of more than $80 per share represents a huge premium compared to Sanofi’s last offer. Medivation's shares are up 42.3% so far in 2016.
Medivation is a biopharma company that is focused on cancer treatments. The company currently has one marketed product, prostate cancer treatment, Xtandi. Xtandi, a blockbuster drug, has the potential to be approved for several additional indications as well as patient populations.
Moreover, pipeline candidate talazoparib, an orally-available PARP inhibitor, represents significant upside potential. PARP inhibitors are currently being considered to be the next major class of therapeutics in oncology. Interest in this area has increased considerably following the announcement of impressive late-stage data on another company’s PARP inhibitor, niraparib, in Jun 2016. Top-line results from Medivation’s first talazoparib registrational study, EMBRACA, in germline-BRCA mutated breast cancer are expected in the first half of 2017.
According to Medivation, the addressable patient population for talazoparib in the U.S. and Europe is about 760k including 10k for the EMBRACA population, while the addressable market opportunity is more than $30 billion.
The Medivation acquisition, if it goes through, will strengthen Pfizer’s cancer franchise which currently consists of products like Ibrance, Xarelto and Sutent. Pfizer is also working on strengthening its immune-oncology pipeline and the Medivation acquisition would be a good strategic fit for the company.
Pfizer is a Zacks Rank #3 (Hold) stock while Medivation is a Zacks Rank #5 (Strong Sell) stock. Actelion Ltd. is a better-ranked stock in the health care sector with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pfizer-Medivation Close to Signing $14B Acquisition Deal?
According to a Financial Times article, Pfizer Inc. (PFE - Free Report) and Medivation, Inc. are close to signing a deal under which Pfizer will acquire Medivation for more than $80 per share (approximately $14 billion).
Medivation has been a part of acquisition talks for quite a while with the company first receiving an offer from French drugmaker Sanofi (SNY - Free Report) . Sanofi had initially approached Medivation with an offer of $52.50 in cash which was rejected by the company.
Last month, Medivation announced that it is open to acquisition talks and entered into confidentiality agreements with several firms that had expressed an interest in exploring a potential transaction. The company also confirmed that it had rejected a sweetened bid from Sanofi under which Sanofi offered $58.00 per share in cash plus a Contingent Value Right (CVR) for talazoparib sales representing a potential payment in 2022 of up to $3.00 per share.
Pfizer’s rumored offer of more than $80 per share represents a huge premium compared to Sanofi’s last offer. Medivation's shares are up 42.3% so far in 2016.
MEDIVATION INC Price
MEDIVATION INC Price | MEDIVATION INC Quote
Why Medivation?
Medivation is a biopharma company that is focused on cancer treatments. The company currently has one marketed product, prostate cancer treatment, Xtandi. Xtandi, a blockbuster drug, has the potential to be approved for several additional indications as well as patient populations.
Moreover, pipeline candidate talazoparib, an orally-available PARP inhibitor, represents significant upside potential. PARP inhibitors are currently being considered to be the next major class of therapeutics in oncology. Interest in this area has increased considerably following the announcement of impressive late-stage data on another company’s PARP inhibitor, niraparib, in Jun 2016. Top-line results from Medivation’s first talazoparib registrational study, EMBRACA, in germline-BRCA mutated breast cancer are expected in the first half of 2017.
According to Medivation, the addressable patient population for talazoparib in the U.S. and Europe is about 760k including 10k for the EMBRACA population, while the addressable market opportunity is more than $30 billion.
The Medivation acquisition, if it goes through, will strengthen Pfizer’s cancer franchise which currently consists of products like Ibrance, Xarelto and Sutent. Pfizer is also working on strengthening its immune-oncology pipeline and the Medivation acquisition would be a good strategic fit for the company.
Pfizer is a Zacks Rank #3 (Hold) stock while Medivation is a Zacks Rank #5 (Strong Sell) stock. Actelion Ltd. is a better-ranked stock in the health care sector with a Zacks Rank #1 (Strong Buy).
PFIZER INC Price
PFIZER INC Price | PFIZER INC Quote
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>